ATE191343T1 - Verwendung von einem azabicyclischen oxadiazol- oder -thiadiazol-verbindung zur behandlung von angstzuständen - Google Patents
Verwendung von einem azabicyclischen oxadiazol- oder -thiadiazol-verbindung zur behandlung von angstzuständenInfo
- Publication number
- ATE191343T1 ATE191343T1 AT95307741T AT95307741T ATE191343T1 AT E191343 T1 ATE191343 T1 AT E191343T1 AT 95307741 T AT95307741 T AT 95307741T AT 95307741 T AT95307741 T AT 95307741T AT E191343 T1 ATE191343 T1 AT E191343T1
- Authority
- AT
- Austria
- Prior art keywords
- branched
- straight
- alkyl
- phenyl
- alkynyl
- Prior art date
Links
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- -1 THIADIAZOLE COMPOUND Chemical class 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 5
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 239000005864 Sulphur Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Chemical group O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 abstract 1
- 150000004867 thiadiazoles Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/332,186 US5488056A (en) | 1994-10-31 | 1994-10-31 | Method for treating anxiety |
| US08/336,589 US5484794A (en) | 1994-11-09 | 1994-11-09 | Method for treating anxiety |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE191343T1 true ATE191343T1 (de) | 2000-04-15 |
Family
ID=26988105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95307741T ATE191343T1 (de) | 1994-10-31 | 1995-10-30 | Verwendung von einem azabicyclischen oxadiazol- oder -thiadiazol-verbindung zur behandlung von angstzuständen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5726193A (de) |
| EP (1) | EP0709093B1 (de) |
| JP (1) | JPH10508027A (de) |
| AT (1) | ATE191343T1 (de) |
| AU (1) | AU4017295A (de) |
| CA (1) | CA2202781A1 (de) |
| DE (1) | DE69516075T2 (de) |
| DK (1) | DK0709093T3 (de) |
| ES (1) | ES2144582T3 (de) |
| GR (1) | GR3033783T3 (de) |
| IL (1) | IL115810A0 (de) |
| PT (1) | PT709093E (de) |
| WO (1) | WO1996013166A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5852037A (en) * | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| WO1997020819A1 (en) * | 1995-12-06 | 1997-06-12 | Eli Lilly And Company | Composition for treating pain |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL83275A (en) * | 1986-09-08 | 1994-02-27 | Novo Nordisk As | Substituted 1, 2, 4- oxadiazolyl piperidine compounds, their preparation and pharmaceutical compositions containing them |
| NZ227841A (en) * | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
| US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| DK198390D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| DK198590D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| US5418240A (en) * | 1990-08-21 | 1995-05-23 | Novo Nordisk A/S | Heterocyclic compounds and their preparation and use |
| DK198490D0 (da) * | 1990-08-21 | 1990-08-21 | Novo Nordisk As | Heterocykliske forbindelser, deres fremstilling og anvendelse |
| US5330994A (en) * | 1992-03-24 | 1994-07-19 | Warner-Lambert Company | Tetrahydropyridine isoxazoline derivatives |
| KR960703908A (ko) * | 1993-08-19 | 1996-08-31 | 안네 세커 | 정신병 치료방법(Antipsychotic method) |
| DK0734259T3 (da) * | 1993-08-19 | 2002-09-30 | Novo Nordisk As | Antipsykotisk fremgangsmåde |
-
1995
- 1995-05-24 US US08/449,165 patent/US5726193A/en not_active Expired - Fee Related
- 1995-10-30 EP EP95307741A patent/EP0709093B1/de not_active Expired - Lifetime
- 1995-10-30 AT AT95307741T patent/ATE191343T1/de not_active IP Right Cessation
- 1995-10-30 CA CA002202781A patent/CA2202781A1/en not_active Abandoned
- 1995-10-30 WO PCT/US1995/014049 patent/WO1996013166A1/en not_active Ceased
- 1995-10-30 JP JP8514809A patent/JPH10508027A/ja not_active Withdrawn
- 1995-10-30 IL IL11581095A patent/IL115810A0/xx unknown
- 1995-10-30 AU AU40172/95A patent/AU4017295A/en not_active Abandoned
- 1995-10-30 ES ES95307741T patent/ES2144582T3/es not_active Expired - Lifetime
- 1995-10-30 PT PT95307741T patent/PT709093E/pt unknown
- 1995-10-30 DE DE69516075T patent/DE69516075T2/de not_active Expired - Fee Related
- 1995-10-30 DK DK95307741T patent/DK0709093T3/da active
-
2000
- 2000-06-27 GR GR20000401482T patent/GR3033783T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5726193A (en) | 1998-03-10 |
| JPH10508027A (ja) | 1998-08-04 |
| EP0709093A2 (de) | 1996-05-01 |
| ES2144582T3 (es) | 2000-06-16 |
| WO1996013166A1 (en) | 1996-05-09 |
| PT709093E (pt) | 2000-08-31 |
| EP0709093A3 (de) | 1996-05-29 |
| IL115810A0 (en) | 1996-01-19 |
| CA2202781A1 (en) | 1996-05-09 |
| AU4017295A (en) | 1996-05-23 |
| EP0709093B1 (de) | 2000-04-05 |
| DE69516075D1 (de) | 2000-05-11 |
| DK0709093T3 (da) | 2000-07-10 |
| GR3033783T3 (en) | 2000-10-31 |
| DE69516075T2 (de) | 2000-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE46899A1 (es) | Derivados de n-fenil-sulfonamida | |
| ES8401486A1 (es) | Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina. | |
| ES2126099T3 (es) | Compuestos heterociclicos y su preparacion y uso. | |
| SE8203887D0 (sv) | Nya trombininhiberande foreningar | |
| CA2337041A1 (en) | Aminomethylcarboxylic acid derivatives | |
| ATE191344T1 (de) | Tetrahydropyridin oxadiazol- oder -thiadiazol- verbindung zur behandlung von angstzuständen | |
| ATE527247T1 (de) | Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung | |
| DE69131759D1 (de) | An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one | |
| DE69516075D1 (de) | Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen | |
| NO168890C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive acylcephalosporinderivater | |
| CA2169838A1 (en) | Antipsychotic method | |
| ATE84532T1 (de) | Cyclische amide. | |
| DK283487A (da) | Thiazolyl-2-yl-imidazo(1,2-a)pyrimidiner, deres fremstilling og brug | |
| CU21554A3 (en) | Obtainment procedure of imidazobenzodiacepine | |
| PH21257A (en) | 11-substituted 5-h,11-pyrrolo,(2,1-c)benzoxazepine and their use as medicaments | |
| NO975094L (no) | Vinylpyrrolidoncefalosporinderivater | |
| DE69735039D1 (de) | Acetylhydrolase des Plättchen aktivierenden Faktors, und entsprechendes Gen | |
| GB9209330D0 (en) | Chemical compounds | |
| ATE178900T1 (de) | 1-azaadamantanderivate als 5-ht4 agonisten oder antagonisten und/oder 5-ht3 antagonisten | |
| ATE68494T1 (de) | Benzofuranderivate und diese enthaltende therapeutische mittel. | |
| ATE163649T1 (de) | Peptide, herstellung und deren verwendung | |
| PT82550A (en) | 1,3 oxathiane derivatives | |
| ES8502704A1 (es) | Un procedimiento para la preparacion de antibioticos b-lactamicos. | |
| FI953618A0 (fi) | Kondensoituneita heterosyklisiä glutamiinijohdannaisia antiproliferatiivisina aineina | |
| DE69617444D1 (de) | Heterocyclische verbindungen zur schmerzbehandlung und deren verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |